- ►biopeptidetech.com [PDF] BR Gedulin, PA Smith, CM Jodka, K Chen, S … - International Journal of …, 2008 - Elsevier Exenatide is a 39-amino acid peptide incretin mimetic approved for adjunctive treatment of type
2 diabetes. It shares several glucoregulatory activities with the mammalian hormone,
glucagon-like peptide-1 (GLP-1). In clinical use, subcutaneous exenatide injections ... Cited by 5 - Related articles - All 4 versions
R Siekmeier, G Scheuch - J Physiol Pharmacol, 2008 - jpp.krakow.pl After more than 80 years of history the American and European Drug Agencies (FDA and
EMEA) approved the first pulmonary delivered version of insulin (Exubera®) from Pfizer/Nektar
early 2006. However, in October 2007, Pfizer announced it would be taking Exubera® off ... Cited by 3 - Related articles - View as HTML - All 5 versions
E Ang, MK Lawrence, CR Heilmann, JA … - Diabetes Technology …, 2009 - liebertonline.com Abstract Background: Long-term safety and efficacy of AIRÒ inhaled insulin (Eli Lilly and
Co., Indianapolis, IN) (AIR is a registered trademark of Alkermes, Inc., Cambridge, MA) in patients
with diabetes and concomitant lung disease remain to be established. Methods: This ... Cited by 1 - Related articles - All 2 versions
A de la Pena, M Seger, K Rave, L Heinemann … - Diabetes Technology …, 2009 - liebertonline.com Abstract Background: In order to assess pharmacokinetic (PK) and glucodynamic (GD) attributes
relevant to the end user of an inhaled insulin, this study examined the exposure and GD effect
of doses of AIRÒ inhaled insulin (Eli Lilly and Co., Indianapolis, IN) (AIR is a registered ... Cited by 1 - Related articles - All 3 versions
BL Silverman, CJ Barnes, BN Campaigne, … - Vascular Health and …, 2007 - pubmedcentral.nih.gov Diabetes mellitus is a significant worldwide health problem, with the incidence of type 2 diabetes
increasing at alarming rates. Insulin resistance and dysregulated blood glucose control are established
risk factors for microvascular complications and cardiovascular disease. Despite the ... Cited by 1 - Related articles - BL Direct - All 8 versions
AH Boss, W Yu, K Ellerman - Drug Development Research - interscience.wiley.com The low proportion of patients achieving glycemic targets is well documented for both type 1
and type 2 diabetes. Postprandial glucose levels are often not monitored but contribute significantly
to total glycemic burden. Prandial rapid-acting insulin analogues were introduced to ... Cited by 1 - Related articles
E González Sarmiento - Archivos de Bronconeumología (Internet), 2007 - Elsevier J Rosenstock, B Zinman, LJ Murphy, SC Clement, P Moore and CK Bowering et al., Inhaled insulin
improves glycemic control when substituted for or added to oral combination therapy in type
2 diabetes: a randomized, controlled trial, Ann Intern Med 143 (2005), pp. 549–558. Related articles
L Zhi-hong, C Ying-li, LI Fang-ping, YAN Xiang, LU … - Chinese Medical Journal, 2008 - cmj.org Background A new inhalable insulin aerosol (Inh-Ins) was developed in China. The aim of this
multicenter clinical study was to evaluate the efficacy and safety of this new Inh-Ins as a treatment
of type 2 diabetes. Regular porcine insulin (RI) was used as a control. Methods This study ... Related articles - Cached - All 6 versions
[CITATION] Inhaled Insulin and Its Effects on the Lungs
